Short answer
A Part D drug is capped at $2,100 in 2026; the Bridge is a flat $50 outside the cap.
For a GLP-1 covered by your Part D plan (for diabetes, cardiovascular risk, or sleep apnea), you pay the plan cost-sharing, and Medicare.gov says yearly out-of-pocket spending on covered Part D drugs is capped at $2,100 in 2026. The new GLP-1 Bridge charges a flat $50 monthly copay, but CMS says it sits outside Part D, so it does not count toward the deductible or the $2,100 cap and no low-income subsidy applies. CMS selected Ozempic, Rybelsus, and Wegovy for price negotiation, with prices effective in 2027.
Start here
What you actually came to find out
Plain answers first. Sources stay below for checking details.
What is the cap?
Medicare.gov says $2,100 out-of-pocket for covered Part D drugs in 2026.
What about the Bridge?
CMS says a flat $50 copay that does not count toward the cap.
Does Extra Help apply to the Bridge?
No. CMS says no low-income subsidy applies under the Bridge.
Will prices change?
CMS says Ozempic, Rybelsus, and Wegovy prices are negotiated for 2027.
Part D cap
$2,100 in 2026
Medicare.gov says covered Part D drug spending is capped at $2,100 in 2026.
Source trail: Medicare.gov
Bridge copay
$50 per month
CMS says the Bridge charges a flat $50 monthly copay.
Source trail: CMS
Outside the cap
Does not count
CMS says the Bridge copay does not count toward the deductible or the cap.
Source trail: CMS
Negotiation
Effective 2027
CMS says Ozempic, Rybelsus, and Wegovy were selected for negotiation.
Source trail: CMS
The real driver is the pathway: a covered Part D prescription benefits from the out-of-pocket cap, while the Bridge copay is a separate flat charge.
Neutral landscape
The shape of the question
Medicare.gov is the main source for the covered-drug path because it sets the yearly out-of-pocket cap.
Source trail: Medicare.gov
The Bridge is billed differently, and CMS says it uses a flat $50 copay outside Part D.
Source trail: CMS
The cap interaction matters because CMS says the Bridge copay does not count toward the deductible or the cap and has no low-income subsidy.
Source trail: CMS
Future cost is changing, since CMS selected several GLP-1 drugs for negotiation effective in 2027.
Source trail: CMS
Curator core
What the authorities say
These sources are here for the reader who wants to check the work. The plain-English answer stays above them.
Source 01
Medicare.gov
Part D Costs
Medicare.gov explains Part D drug costs, including the yearly out-of-pocket cap that reaches $2,100 in 2026 and then triggers catastrophic coverage.
Source framing
Medicare.gov says yearly out-of-pocket spending on covered Part D drugs is capped at $2,100 in 2026, after which you pay nothing more for covered drugs that year.
Strongest for: the Part D out-of-pocket cap that limits drug spending
Read at Medicare.govSource 02
CMS
Medicare GLP-1 Bridge
CMS explains the Medicare GLP-1 Bridge, a short-term demonstration giving eligible Part D beneficiaries access to certain GLP-1 drugs from July 1, 2026 through December 31, 2027.
Source framing
CMS says the Medicare GLP-1 Bridge is a short-term demonstration running July 1, 2026 through December 31, 2027, using a central processor and a flat monthly copay outside the Part D benefit.
Strongest for: how the new Medicare GLP-1 Bridge works and who is eligible
Read at CMSSource 03
CMS
Medicare Drug Price Negotiation Selections
CMS announced the second cycle of Medicare drug price negotiations, which selected Ozempic, Rybelsus, and Wegovy, with negotiated prices effective in 2027.
Source framing
CMS says Ozempic, Rybelsus, and Wegovy were selected for Medicare drug price negotiation, with negotiated prices effective in 2027, and that Part D out-of-pocket spending is capped at $2,000 a year.
Strongest for: GLP-1 drug price negotiation and the Part D out-of-pocket cap
Read at CMSSource 04
KFF
GLP-1s in Medicare and Medicaid
KFF tracks GLP-1 coverage across Medicare and Medicaid, including how many states cover obesity treatment and how the Part D out-of-pocket cap rises.
Source framing
KFF reports that coverage of GLP-1s for obesity is required for medical indications but optional for weight loss in Medicaid, with only 13 states covering obesity treatment as of January 2026.
Strongest for: the state count for Medicaid obesity coverage and out-of-pocket-cap figures
Read at KFFPlain-English forks
The forks people face
Most retirement questions hide a few smaller decisions. These are the practical pieces that change the plan.
Is the drug covered by Part D or the Bridge?
Why it matters: A Part D drug benefits from the cap; the Bridge is a flat copay.
In real life: This fork sets how you are billed.
What to look at: What to look at: the diagnosis and pathway.
Do you usually get Extra Help?
Why it matters: CMS says Extra Help does not apply to the Bridge copay.
In real life: This fork matters most for lower-income beneficiaries.
What to look at: What to look at: the Bridge cost rules.
Are you planning for 2027?
Why it matters: Negotiated prices and a higher cap both arrive in 2027.
In real life: This fork affects future budgeting.
What to look at: What to look at: the CMS negotiation list and KFF cap figures.
Common questions
Quick answers
Short, plain answers for the questions people usually have next. The source trail stays available below.
Is there a limit on what I pay for GLP-1 drugs on Medicare?+
Medicare.gov says yearly out-of-pocket spending on covered Part D drugs is capped at $2,100 in 2026, after which you pay nothing more for covered drugs that year.
What does the GLP-1 Bridge cost?+
CMS says the Bridge charges a flat $50 monthly copay, and that this copay does not count toward the Part D deductible or out-of-pocket cap.
Does Extra Help lower the Bridge copay?+
No. CMS says no low-income subsidy is provided under the Bridge, so the $50 copay applies to everyone eligible.
Will GLP-1 prices drop under Medicare?+
CMS says Ozempic, Rybelsus, and Wegovy were selected for Medicare drug price negotiation, with negotiated prices effective in 2027.
Does the out-of-pocket cap rise after 2026?+
KFF reports the cap is indexed to rise each year, increasing to $2,400 in 2027.
How this page is curated
This page uses Medicare.gov Part D costs, the CMS GLP-1 Bridge page, the CMS drug-price-negotiation announcement, and KFF for the future-year cap figure. It keeps the Part D path and the Bridge separate because they are billed differently.
Read the planner methodologyTrust anchor
Sources used on this page
Every source named above is listed here in one place.
CMS. Medicare GLP-1 Bridge
https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridgeCMS. Medicare Drug Price Negotiation Selections
https://www.cms.gov/newsroom/press-releases/hhs-announces-15-additional-drugs-selected-medicare-drug-price-negotiations-continued-effort-lowerKFF. GLP-1s in Medicare and Medicaid
https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/Medicare.gov. Part D Costs
https://www.medicare.gov/health-drug-plans/part-d/basics/costs
Before you act on this
This plan is educational. It is not personalized financial, tax, or insurance advice. Projections illustrate the math, they do not predict the future. Talk to your own licensed financial professional before acting on any of it.